search icon
lvtx-img

LAVA Therapeutics NV, Common Stock

LVTX

NSQ

$1.26

-$0.06

(-4.53%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$33.41M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
89.45K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.45
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.85 L
$2.53 H
$1.26

About LAVA Therapeutics NV, Common Stock

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLVTXSectorS&P500
1-Week Return4.33%1.39%1.18%
1-Month Return5.16%-4.97%6.44%
3-Month Return2.71%-11.13%-0.73%
6-Month Return-17.19%-10.21%-2.01%
1-Year Return-44.33%-6.5%12.12%
3-Year Return-55.83%0.1%42.84%
5-Year Return-90.73%28.49%93.86%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue3.75M5.00M19.39M6.77M11.98M[{"date":"2020-12-31","value":19.32,"profit":true},{"date":"2021-12-31","value":25.79,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.91,"profit":true},{"date":"2024-12-31","value":61.79,"profit":true}]
Cost of Revenue15.70M--3.48M467.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":22.18,"profit":true},{"date":"2024-12-31","value":2.97,"profit":true}]
Gross Profit(11.95M)5.00M19.39M3.29M11.52M[{"date":"2020-12-31","value":-61.65,"profit":false},{"date":"2021-12-31","value":25.79,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":16.95,"profit":true},{"date":"2024-12-31","value":59.38,"profit":true}]
Gross Margin(319.03%)100.00%100.00%48.56%96.10%[{"date":"2020-12-31","value":-319.03,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":48.56,"profit":true},{"date":"2024-12-31","value":96.1,"profit":true}]
Operating Expenses3.59M49.35M54.23M46.54M41.67M[{"date":"2020-12-31","value":6.62,"profit":true},{"date":"2021-12-31","value":91.01,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.82,"profit":true},{"date":"2024-12-31","value":76.85,"profit":true}]
Operating Income(14.67M)(44.35M)(34.84M)(43.25M)(29.69M)[{"date":"2020-12-31","value":-1467300000,"profit":false},{"date":"2021-12-31","value":-4435300000,"profit":false},{"date":"2022-12-31","value":-3483800000,"profit":false},{"date":"2023-12-31","value":-4325300000,"profit":false},{"date":"2024-12-31","value":-2969300000,"profit":false}]
Total Non-Operating Income/Expense(1.50M)(1.46M)3.44M4.53M8.45M[{"date":"2020-12-31","value":-17.81,"profit":false},{"date":"2021-12-31","value":-17.3,"profit":false},{"date":"2022-12-31","value":40.66,"profit":true},{"date":"2023-12-31","value":53.57,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(15.88M)(45.19M)(31.66M)(41.70M)(24.48M)[{"date":"2020-12-31","value":-1588400000,"profit":false},{"date":"2021-12-31","value":-4519000000,"profit":false},{"date":"2022-12-31","value":-3165800000,"profit":false},{"date":"2023-12-31","value":-4169500000,"profit":false},{"date":"2024-12-31","value":-2448400000,"profit":false}]
Income Taxes43.00K157.00K249.00K279.00K630.00K[{"date":"2020-12-31","value":6.83,"profit":true},{"date":"2021-12-31","value":24.92,"profit":true},{"date":"2022-12-31","value":39.52,"profit":true},{"date":"2023-12-31","value":44.29,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(15.93M)(45.35M)(31.91M)(41.97M)(25.11M)[{"date":"2020-12-31","value":-1592700000,"profit":false},{"date":"2021-12-31","value":-4534700000,"profit":false},{"date":"2022-12-31","value":-3190700000,"profit":false},{"date":"2023-12-31","value":-4197400000,"profit":false},{"date":"2024-12-31","value":-2511400000,"profit":false}]
Income From Continuous Operations(13.58M)(45.35M)(31.91M)(41.97M)(25.11M)[{"date":"2020-12-31","value":-1358400000,"profit":false},{"date":"2021-12-31","value":-4534700000,"profit":false},{"date":"2022-12-31","value":-3190700000,"profit":false},{"date":"2023-12-31","value":-4197400000,"profit":false},{"date":"2024-12-31","value":-2511400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(15.93M)(45.35M)(31.91M)(41.97M)(25.11M)[{"date":"2020-12-31","value":-1592700000,"profit":false},{"date":"2021-12-31","value":-4534700000,"profit":false},{"date":"2022-12-31","value":-3190700000,"profit":false},{"date":"2023-12-31","value":-4197400000,"profit":false},{"date":"2024-12-31","value":-2511400000,"profit":false}]
EPS (Diluted)-(13.15)(1.34)(1.59)(0.89)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1315,"profit":false},{"date":"2022-12-31","value":-134,"profit":false},{"date":"2023-12-31","value":-159,"profit":false},{"date":"2024-12-31","value":-89.45,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LVTX
Cash Ratio 6.42
Current Ratio 6.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LVTX
ROA (LTM) -23.02%
ROE (LTM) -73.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LVTX
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.36

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LVTX
Trailing PE NM
Forward PE NM
P/S (TTM) 6.98
P/B 1.35
Price/FCF 17
EV/R 2.12
EV/Ebitda 0.81

FAQs

What is LAVA Therapeutics NV share price today?

LAVA Therapeutics NV (LVTX) share price today is $1.26

Can Indians buy LAVA Therapeutics NV shares?

Yes, Indians can buy shares of LAVA Therapeutics NV (LVTX) on Vested. To buy LAVA Therapeutics NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LVTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of LAVA Therapeutics NV be purchased?

Yes, you can purchase fractional shares of LAVA Therapeutics NV (LVTX) via the Vested app. You can start investing in LAVA Therapeutics NV (LVTX) with a minimum investment of $1.

How to invest in LAVA Therapeutics NV shares from India?

You can invest in shares of LAVA Therapeutics NV (LVTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in LVTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in LAVA Therapeutics NV shares
What is LAVA Therapeutics NV 52-week high and low stock price?

The 52-week high price of LAVA Therapeutics NV (LVTX) is $2.53. The 52-week low price of LAVA Therapeutics NV (LVTX) is $0.85.

What is LAVA Therapeutics NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of LAVA Therapeutics NV (LVTX) is 1.35

What is the Market Cap of LAVA Therapeutics NV?

The market capitalization of LAVA Therapeutics NV (LVTX) is $33.41M

What is LAVA Therapeutics NV’s stock symbol?

The stock symbol (or ticker) of LAVA Therapeutics NV is LVTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top